{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:28:43Z","timestamp":1785882523654,"version":"3.56.0"},"reference-count":23,"publisher":"Impact Journals, LLC","issue":"48","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,6,22]]},"DOI":"10.18632\/oncotarget.25622","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T14:23:28Z","timestamp":1529677408000},"page":"28897-28902","source":"Crossref","is-referenced-by-count":36,"title":["Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis"],"prefix":"10.18632","volume":"9","author":[{"given":"Dai","family":"Chihara","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan H.","family":"Fowler","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Oki","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Fanale","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Westin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Yoon","family":"Cheah","sequence":"additional","affiliation":[{"name":"Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia"},{"name":"Department of Haematology, Pathwest Laboratory Medicine WA, Nedlands, WA, Australia"},{"name":"Medical School, University of Western Australia, Crawley, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,6,22]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS Lymphoma","volume":"35","author":"DeAngelis","year":"2017","journal-title":"J Clin Oncol"},{"key":"2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.14073","article-title":"Trends in primary central nervous system lymphoma incidence and survival in the U.S","volume":"174","author":"Engels","year":"2016","journal-title":"Br J Haematol"},{"key":"3","unstructured":"Network NCC. Central Nervous System Cancers. 2017."},{"key":"4","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1200\/JCO.2003.03.108","article-title":"High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962","volume":"21","author":"Teodorovic","year":"2003","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10","volume":"20","author":"Schultz","year":"2002","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000055310","article-title":"Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients","volume":"60","author":"Villa","year":"2001","journal-title":"Oncology"},{"key":"7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2000.18.3.519","article-title":"Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma","volume":"18","author":"Trotter","year":"2000","journal-title":"J Clin Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1200\/JCO.1992.10.4.635","article-title":"Combined modality therapy for primary CNS lymphoma","volume":"10","author":"Kher","year":"1992","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","article-title":"Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"key":"10","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","article-title":"Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma","volume":"25","author":"Abrey","year":"2007","journal-title":"J Clin Oncol"},{"key":"11","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Faivre","year":"2015","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Hemmaway","year":"2016","journal-title":"Lancet Haematol"},{"key":"13","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.2005.07.109","article-title":"Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group","volume":"23","author":"Ponzoni","year":"2005","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clml.2017.09.012","article-title":"Extranodal marginal zone lymphoma of the central nervous system","volume":"18","author":"Cherry","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/nox187","article-title":"The elderly left behind - changes in survival trends of primary central nervous system lymphoma over the past four decades","volume":"20","author":"Grommes","year":"2018","journal-title":"Neuro Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood.V128.22.783.783","article-title":"Single-agent ibrutinib in recurrent\/refractory central nervous system lymphoma","volume":"128","author":"DeAngelis","year":"2016","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V128.22.785.785","article-title":"Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a \u201cProof of Concept\u201d Phase II Study of the French LOC Network","volume":"128","author":"Chevrier","year":"2016","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood.V128.22.784.784","article-title":"Ibrutinib monotherapy in relapse or refractory primary CNS lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network","volume":"128","author":"Clavert","year":"2016","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma","volume":"7","author":"Viale","year":"2017","journal-title":"Cancer Discov"},{"key":"20","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Ducar","year":"2016","journal-title":"Blood"},{"key":"21","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","article-title":"Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas","volume":"18","author":"Vital","year":"2012","journal-title":"Clin Cancer Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma","volume":"31","author":"Chen","year":"2017","journal-title":"Cancer Cell"},{"key":"23","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/1055-9965.EPI-05-0549","article-title":"Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study","volume":"15","author":"Holly","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T18:48:05Z","timestamp":1589050085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,22]]},"references-count":23,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2018,6,22]]}},"alternative-id":["25622","29988979"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.25622","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,22]]}}}